Otonomy Stock Price, News & Analysis (NASDAQ:OTIC)

$5.85 0.17 (2.99 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$5.85
Today's Range$5.70 - $5.90
52-Week Range$2.80 - $21.15
Volume309,336 shs
Average Volume326,136 shs
Market Capitalization$177.47 million
P/E Ratio-1.81
Dividend YieldN/A
Beta3.33

About Otonomy (NASDAQ:OTIC)

Otonomy logoOtonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:OTIC
CUSIPN/A
Phone+1-619-3232200

Debt

Debt-to-Equity RatioN/A
Current Ratio13.02%
Quick Ratio12.91%

Price-To-Earnings

Trailing P/E Ratio-1.81114551083591
Forward P/E Ratio-2.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$680,000.00
Price / Sales261.01
Cash FlowN/A
Price / CashN/A
Book Value$6.38 per share
Price / Book0.92

Profitability

Trailing EPS($3.23)
Net Income$-110,580,000.00
Net Margins-7,899.03%
Return on Equity-60.74%
Return on Assets-56.22%

Miscellaneous

Employees139
Outstanding Shares30,340,000

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy Inc (NASDAQ:OTIC) posted its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.15. The biopharmaceutical company earned $0.28 million during the quarter, compared to the consensus estimate of $0.43 million. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The business's revenue was down 12.8% compared to the same quarter last year. View Otonomy's Earnings History.

Where is Otonomy's stock going? Where will Otonomy's stock price be in 2018?

4 equities research analysts have issued 12-month price objectives for Otonomy's shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate Otonomy's share price to reach $10.00 in the next twelve months. View Analyst Ratings for Otonomy.

Who are some of Otonomy's key competitors?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:

  • Jay Lichter Ph.D., Independent Chairman of the Board (Age 55)
  • David A. Weber Ph.D., President, Chief Executive Officer, Director (Age 57)
  • Paul E. Cayer, Chief Financial and Business Officer (Age 55)
  • Robert Michael Savel II, Chief Technical Officer (Age 49)
  • Kathie M. Bishop Ph.D., Chief Scientific Officer (Age 51)
  • Eric J. Loumeau, Chief Compliance Officer, General Counsel, Secretary (Age 54)
  • Dean Hakanson M.D., Chief Medical Officer (Age 65)
  • Vickie L. Capps, Independent Director (Age 55)
  • Iain R. McGill, Independent Director (Age 44)
  • George J. Morrow, Independent Director (Age 65)

Who owns Otonomy stock?

Otonomy's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (6.27%), Schwab Charles Investment Management Inc. (0.37%) and Acadian Asset Management LLC (0.12%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.

Who bought Otonomy stock? Who is buying Otonomy stock?

Otonomy's stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Schwab Charles Investment Management Inc. and Acadian Asset Management LLC. View Insider Buying and Selling for Otonomy.

How do I buy Otonomy stock?

Shares of Otonomy can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of Otonomy stock can currently be purchased for approximately $5.85.

How big of a company is Otonomy?

Otonomy has a market capitalization of $177.47 million and generates $680,000.00 in revenue each year. The biopharmaceutical company earns $-110,580,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Otonomy employs 139 workers across the globe.

How can I contact Otonomy?

Otonomy's mailing address is 4796 Executive Dr, SAN DIEGO, CA 92121-3090, United States. The biopharmaceutical company can be reached via phone at +1-619-3232200 or via email at [email protected]


MarketBeat Community Rating for Otonomy (OTIC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Otonomy (NASDAQ:OTIC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.503.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$10.00$32.00
Price Target Upside: 93.24% upside93.24% upside177.78% upside69.76% upside

Otonomy (NASDAQ:OTIC) Consensus Price Target History

Price Target History for Otonomy (NASDAQ:OTIC)

Otonomy (NASDAQ:OTIC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$8.00N/AView Rating Details
8/31/2017CowenReiterated RatingOutperform$55.00 -> $9.00LowView Rating Details
8/31/2017SunTrust BanksReiterated RatingBuy$45.00 -> $15.00HighView Rating Details
8/30/2017JPMorgan Chase & Co.DowngradeOverweight -> Neutral$28.00 -> $8.00HighView Rating Details
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Otonomy (NASDAQ:OTIC) Earnings History and Estimates Chart

Earnings by Quarter for Otonomy (NASDAQ:OTIC)

Otonomy (NASDAQ OTIC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.84)($0.69)$0.43 million$0.28 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.80)($0.77)$0.43 million$0.33 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.84)($0.89)$0.50 million$0.36 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.93)($0.88)$0.49 million$0.27 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.98)($0.91)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.93)($0.98)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.85)($0.91)ViewN/AView Earnings Details
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details
11/12/2014Q3 2014($0.66)($1.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Otonomy (NASDAQ:OTIC) Earnings Estimates

2018 EPS Consensus Estimate: ($3.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.74)($0.74)($0.74)
Q2 20181($0.78)($0.78)($0.78)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.81)($0.81)($0.81)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Otonomy (NASDAQ:OTIC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Otonomy (NASDAQ OTIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.70%
Institutional Ownership Percentage: 60.60%
Insider Trades by Quarter for Otonomy (NASDAQ:OTIC)
Institutional Ownership by Quarter for Otonomy (NASDAQ:OTIC)

Otonomy (NASDAQ OTIC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/26/2017Eric J. LoumeauInsiderSell3,522$18.59$65,473.98View SEC Filing  
11/21/2016Carl LebelInsiderSell10,625$18.07$191,993.7513,001View SEC Filing  
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.008,920View SEC Filing  
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.009,610View SEC Filing  
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.0017,603View SEC Filing  
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.001,256View SEC Filing  
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.009,610View SEC Filing  
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.5617,603View SEC Filing  
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20539View SEC Filing  
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60539View SEC Filing  
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.009,610View SEC Filing  
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.008,920View SEC Filing  
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.009,610View SEC Filing  
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20539View SEC Filing  
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.001,256View SEC Filing  
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Otonomy (NASDAQ OTIC) News Headlines

Source:
DateHeadline
$250,000.00 in Sales Expected for Otonomy Inc (OTIC) This Quarter$250,000.00 in Sales Expected for Otonomy Inc (OTIC) This Quarter
www.americanbankingnews.com - January 21 at 8:48 AM
Otonomy Inc (OTIC) Expected to Post Earnings of -$0.67 Per ShareOtonomy Inc (OTIC) Expected to Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - January 19 at 5:26 AM
Otonomy (OTIC) Downgraded by Zacks Investment Research to "Sell"Otonomy (OTIC) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - January 17 at 9:18 AM
Otonomy Provides Corporate and Product Pipeline UpdateOtonomy Provides Corporate and Product Pipeline Update
finance.yahoo.com - January 9 at 10:07 AM
Otonomy to Present at the J.P. Morgan Healthcare ConferenceOtonomy to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 10:06 AM
Otonomy Inc (OTIC) Given Consensus Rating of "Hold" by BrokeragesOtonomy Inc (OTIC) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 3 at 1:58 AM
ETFs with exposure to Otonomy, Inc. : December 28, 2017ETFs with exposure to Otonomy, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:39 PM
Otonomy, Inc. :OTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Otonomy, Inc. :OTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 2:39 PM
Otonomy, Inc. (OTIC) Expected to Announce Quarterly Sales of $250,000.00Otonomy, Inc. (OTIC) Expected to Announce Quarterly Sales of $250,000.00
www.americanbankingnews.com - December 18 at 4:16 PM
Otonomy, Inc. (OTIC) Receives Consensus Rating of "Hold" from AnalystsOtonomy, Inc. (OTIC) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 9 at 1:48 AM
Otonomy, Inc. to Post Q4 2017 Earnings of ($0.75) Per Share, SunTrust Banks Forecasts (OTIC)Otonomy, Inc. to Post Q4 2017 Earnings of ($0.75) Per Share, SunTrust Banks Forecasts (OTIC)
www.americanbankingnews.com - December 1 at 3:52 PM
BRIEF-Otonomy Inc Immediately Discontinuing Commercial Support For OtiprioBRIEF-Otonomy Inc Immediately Discontinuing Commercial Support For Otiprio
www.businessinsider.com - November 29 at 10:17 AM
Otonomy, Inc. (OTIC) Expected to Announce Earnings of -$0.66 Per ShareOtonomy, Inc. (OTIC) Expected to Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - November 28 at 11:14 AM
Otonomy (OTIC) Says Discussions Underway to Divest OTIPRIOOtonomy (OTIC) Says Discussions Underway to Divest OTIPRIO
www.streetinsider.com - November 28 at 10:30 AM
Otonomy Announces Plan to Focus Resources on Development ProgramsOtonomy Announces Plan to Focus Resources on Development Programs
finance.yahoo.com - November 27 at 4:39 PM
Otonomy (OTIC) vs. The Competition Head-To-Head ComparisonOtonomy (OTIC) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - November 20 at 11:19 AM
Otonomy Sees Unusually High Options Volume (OTIC)Otonomy Sees Unusually High Options Volume (OTIC)
www.americanbankingnews.com - November 18 at 2:28 AM
Otonomy, Inc. (OTIC) Upgraded by Zacks Investment Research to BuyOtonomy, Inc. (OTIC) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - November 14 at 6:30 AM
Otonomy, Inc. (OTIC) Given Consensus Recommendation of "Hold" by BrokeragesOtonomy, Inc. (OTIC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 14 at 1:50 AM
Equities Analysts Issue Forecasts for Otonomy, Inc.s FY2017 Earnings (OTIC)Equities Analysts Issue Forecasts for Otonomy, Inc.'s FY2017 Earnings (OTIC)
www.americanbankingnews.com - November 13 at 2:36 AM
Otonomy, Inc. (OTIC) Short Interest UpdateOtonomy, Inc. (OTIC) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
Piper Jaffray Companies Reiterates Hold Rating for Otonomy, Inc. (OTIC)Piper Jaffray Companies Reiterates Hold Rating for Otonomy, Inc. (OTIC)
www.americanbankingnews.com - November 11 at 9:42 AM
Otonomy, Inc. (OTIC) Expected to Post Quarterly Sales of $680,000.00Otonomy, Inc. (OTIC) Expected to Post Quarterly Sales of $680,000.00
www.americanbankingnews.com - November 11 at 4:39 AM
Otonomy Rips 90% After Menieres Disease Drug Achieves Primary EndpointOtonomy Rips 90% After Meniere's Disease Drug Achieves Primary Endpoint
www.benzinga.com - November 10 at 7:52 PM
Otonomy Inc. (OTIC) Is Rising On Phase 3 Study ResultsOtonomy Inc. (OTIC) Is Rising On Phase 3 Study Results
www.rttnews.com - November 10 at 7:52 PM
Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.
finance.yahoo.com - November 10 at 2:51 PM
Otonomy Gets Another Vote of Confidence from SunTrustOtonomy Gets Another Vote of Confidence from SunTrust
finance.yahoo.com - November 10 at 2:51 PM
Otonomy, Inc. (OTIC) Expected to Announce Earnings of -$0.76 Per ShareOtonomy, Inc. (OTIC) Expected to Announce Earnings of -$0.76 Per Share
www.americanbankingnews.com - November 9 at 9:22 PM
Otonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary Endpoint - StreetInsider.comOtonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary Endpoint - StreetInsider.com
www.streetinsider.com - November 9 at 3:26 PM
Otonomy, Inc. (OTIC) Announces  Earnings ResultsOtonomy, Inc. (OTIC) Announces Earnings Results
www.americanbankingnews.com - November 9 at 1:14 PM
Otonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary EndpointOtonomy (OTIC) Says AVERTS-2 Phase 3 Trial of OTIVIDEX Achieved Primary Endpoint
www.streetinsider.com - November 9 at 10:53 AM
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménières DiseaseOtonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
finance.yahoo.com - November 9 at 10:52 AM
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateOtonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 10:52 AM
Otonomy reports 3Q lossOtonomy reports 3Q loss
finance.yahoo.com - November 9 at 10:52 AM
Why Otonomy Shares Are SkyrocketingWhy Otonomy Shares Are Skyrocketing
finance.yahoo.com - November 9 at 10:52 AM
Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech MoversSage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers
finance.yahoo.com - November 9 at 10:52 AM
Otonomy Inc (OTIC) Sparks Optimism Among Investors; Here’s WhyOtonomy Inc (OTIC) Sparks Optimism Among Investors; Here’s Why
finance.yahoo.com - November 9 at 10:51 AM
ETFs with exposure to Otonomy, Inc. : November 6, 2017ETFs with exposure to Otonomy, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 8:22 AM
Comparing Otonomy (OTIC) & Its PeersComparing Otonomy (OTIC) & Its Peers
www.americanbankingnews.com - November 5 at 11:14 AM
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate UpdateOtonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - November 2 at 7:25 AM
Otonomy Inc (OTIC) Scheduled to Post Quarterly Earnings on WednesdayOtonomy Inc (OTIC) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
Otonomy, Inc. (OTIC) Receives Average Recommendation of "Hold" from AnalystsOtonomy, Inc. (OTIC) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 20 at 2:48 AM
Bottom Fishing With Cash-Rich BiotechsBottom Fishing With Cash-Rich Biotechs
finance.yahoo.com - October 3 at 2:14 AM
Otonomy, Inc. (OTIC) Short Interest Down 40.6% in SeptemberOtonomy, Inc. (OTIC) Short Interest Down 40.6% in September
www.americanbankingnews.com - September 30 at 3:26 AM
Otonomy, Inc. (OTIC) Receives Consensus Recommendation of "Hold" from AnalystsOtonomy, Inc. (OTIC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 25 at 2:38 AM
$450,000.00 in Sales Expected for Otonomy, Inc. (OTIC) This Quarter$450,000.00 in Sales Expected for Otonomy, Inc. (OTIC) This Quarter
www.americanbankingnews.com - September 15 at 5:20 AM
-$0.76 EPS Expected for Otonomy, Inc. (OTIC) This Quarter-$0.76 EPS Expected for Otonomy, Inc. (OTIC) This Quarter
www.americanbankingnews.com - September 13 at 4:28 PM
Otonomy Provides Business and Financial UpdateOtonomy Provides Business and Financial Update
finance.yahoo.com - September 13 at 7:33 AM
Otonomy Fails Phase III - Best To AvoidOtonomy Fails Phase III - Best To Avoid
seekingalpha.com - September 6 at 7:19 AM
Otonomy Sees Unusually Large Options Volume (OTIC)Otonomy Sees Unusually Large Options Volume (OTIC)
www.americanbankingnews.com - September 3 at 1:26 AM

SEC Filings

Otonomy (NASDAQ:OTIC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Otonomy (NASDAQ:OTIC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Otonomy (NASDAQ OTIC) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.